Novo Nordisk Collaboration Program(s)

About Gensaic

Gensaic is an early-stage biotech leveraging a proprietary platform, FORGE™, to discover and design novel protein-based delivery systems for metabolic diseases. The company has gained significant validation through a major collaboration with Novo Nordisk, with a potential value of up to $354 million per target. With a strong founding team and experienced board, Gensaic is positioned at the intersection of AI-driven protein design and the high-demand field of metabolic therapeutics, though its technology remains in the pre-clinical discovery phase.

Therapeutic Areas